Colorectal Cancer: Zaltrap Efficacy for BRAF and RAS Mutations
Colorectal Cancer: Zaltrap Efficacy for BRAF and RAS Mutations
Medical Supporter — Information Notice
This article is a summary of international medical information and is not medical advice; it cannot replace the diagnosis or treatment plan of your attending physician. The medical technologies, drug information and clinical data presented here are compiled from public literature and official statements of major Japanese medical institutions; the applicability and outcome of any therapy vary with each patient and must be assessed individually by a qualified physician.
- August 21, 2017
- Reading time: 1 minute
This article discusses WCG 2017 findings regarding Aflibercept (brand name: Zaltrap, known as Soft Cancer Arrest Injection in Taiwan), a second-line therapy for colorectal cancer. This drug shows higher efficacy in patients with BRAF gene mutations or RAS wild-type gene mutations.
Presented by Dr. Sabine Tejpar from University Hospital Leuven, Belgium, at the ESMO 19th Gastrointestinal Cancer Conference (WCGC2017) held June 28-July 1 in Barcelona, Spain. This analysis examined tumor markers and assessed DNA/RNA from patient samples across 591 participants.
For KRAS gene exon2 wild-type analysis (281 patients), the median overall survival (OS) was 11.6 months (95% CI: 10.5-15.9) in the placebo group and 14.9 months (95% CI: 12.4-18.0) in the Zaltrap group.
For KRAS gene exon2 mutation (201 patients), median OS was 10.6 months (95% CI: 8.1-14.0) in the placebo group and 12.6 months (95% CI: 10.2-14.5) in the Zaltrap group.
For RAS wild-type analysis (218 patients), median OS was 11.7 months (95% CI: 10.1-15.9) in the placebo group and 16.0 months (95% CI: 12.7-22.8) in the Zaltrap group.
For BRAF wild-type analysis (446 patients), median OS was 12.4 months (95% CI: 10.7-15.1) in the placebo group and 13.0 months (95% CI: 12.4-15.9) in the Zaltrap group.
For BRAF gene mutation (36 patients), median OS was 5.5 months (95% CI: 3.5-10.6) in the placebo group and 10.3 months (95% CI: 5.3-NA) in the Zaltrap group.
According to Dr. Tejpar, for advanced colorectal cancer with BRAF mutations receiving second-line therapy, the median OS of 10.3 months in the Zaltrap group exceeds that observed with EGFR antibody medications.
#Colorectal Cancer
-
Clinical Trial Drug
(Lung Cancer) Topotecan and Topotecan + Berzosertib Show Promising Results in Phase II Trial. (Lung Cancer) HER2 Gene Mutation Non-Small Cell Lung Cancer: Is Enhertu Effective? (Lung Cancer) Is Anti-B7-H3 Antibody DS-7300 Effective?
Medical Supporter was formerly certified as an international medical visa guarantor by Japan's Ministry of Foreign Affairs and the Ministry of Economy, Trade and Industry (B-066).
Considering medical care in Japan? Need information and support?
We help you organize the information needed for medical travel to Japan, liaise with Japanese medical institutions, and arrange a second-opinion consultation.The first consultation is free; an advisor will help you clarify the next steps.
Figure 1
Figure 2
Figure 3
Figure 4